How to appeal an Aetna compounded glp-1 denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for compounded glp-1

Cited policy: Aetna Clinical Policy Bulletin — Weight Reduction Medications (retroactive reimbursement)

Standard PA criteria for branded GLP-1. No specific provision for compounded retroactive reimbursement.

How Aetna denies compounded glp-1 — and how to counter it

Where Aetna pushes back: 1) Compounded never covered — no retroactive eligibility; 2) Out-of-network pharmacy — no reimbursement.

Counter-arguments that hold up: For purchases during FDA shortage period (semaglutide before Feb 21, 2025; tirzepatide before Dec 19, 2024), 21 USC §353a(b)(2)(A) explicit shortage exemption applies. Plan language conflating 'FDA-approved' with 'covered' is overbroad. If plan covers ANY compounded medications (topical pain creams, BHRT), categorical exclusion of compounded GLP-1 is arbitrary. Demand SPD section + ERISA §503 fair-review documents.

What Aetna typically denies for compounded glp-1

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For compounded glp-1, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the compounded glp-1 treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Compounded sema injectable
• Compounded sema oral
• Compounded tirz injectable
• Sema + B12 combo
• Tirz + B12 combo
• Reimbursement past sema

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.